top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

99.56 +0.65 (+0.65%)
Streaming Delayed Price Updated: 12:56 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 440,070
Open 98.43
Bid (Size) 99.50 (100)
Ask (Size) 99.62 (300)
Prev. Close 98.91
Today's Range 98.13 - 99.89
52wk Range 53.56 - 109.28
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Monday's session: top gainers and losers in the S&P500 index ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill

Performance

YTD
+43.2%
+43.2%
1 Month
-2.4%
-2.4%
3 Month
+17.4%
+17.4%
6 Month
+44.8%
+44.8%
1 Year
+45.5%
+45.5%

More News

Read More
News headline image
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Announces Change to its Board of Directors
From Incyte
Via Business Wire
News headline image
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
From Incyte
Via Business Wire
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
From Incyte
Via Business Wire
News headline image
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
2 S&P 500 Stocks Worth Investigating and 1 We Brush Off
Via StockStory
Topics Stocks
News headline image
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
From Incyte
Via Business Wire
News headline image
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
News headline image
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
From Incyte
Via Business Wire
News headline image
Top S&P500 movers in Friday's session ↗
Via Chartmill
News headline image
Gapping S&P500 stocks in Friday's session ↗
Via Chartmill
News headline image
INCYTE CORP (NASDAQ:INCY) Fits Minervini Trend Template with Strong Growth Momentum ↗
Via Chartmill
News headline image
2 Growth Stocks Set to Flourishand 1 Facing Challenges
Via StockStory
News headline image
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know
Via StockStory
Topics Economy
News headline image
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 99.56
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 12/31/25 12:56 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 22.14B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 22B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page